跳到正文
原文
Endpoints News 生物医药· Max Gelman·· 11 天前AI 评分23

Zura Bio 报告 II 期临床失败,股价暴跌

Zura reports Phase 2 flop in painful skin disorder, stock nosedives

AI 导读

Zura Bio 报告其在治疗一种顽固皮肤疾病的 II 期临床试验中失败,公司股价大幅下跌。

正文

A small biotech’s stock col­lapsed af­ter the com­pa­ny re­port­ed a Phase 2 fail­ure in a de­bil­i­tat­ing skin con­di­tion.

Zu­ra Bio said Mon­day morn­ing that both …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news